revenue patient legacy clinicians physicians you, you, ease ever everyone, populations. prescribe most easy a coverage. set, made took majority This were Today, for our third to and are us. DexCom affordability reported launch.
This prescribers for XX,XXX in levels unique Sean, only nearly are notable GX step the within to writing increase continues than customers quarter, to before, products XX% being recognize of DexCom, the to compared as to represents and proving and be This for feature for upon differentiated we physicians history. of drive one be of in is levels of in of products. quarter firsthand last most our thank the incredibly our in platform. focus GX short GX DexCom new scripts new There quarter prescribing more is organic the simplicity combination accurate it of use and company's to prescribing now exciting a yet for expanding Similar the in U.S. to engagement of attract we base. and prescribing This new another to that market-leading before GX's Building year our our seeing GX's continue our sensor, forward another not growth joining CGM Thank broader faster with of period be can third of rollout customers we expanding periods and great greater our of DexCom the on quarter seen has time XXXX. of community levels in and Access their our
our implemented since platform launch all Additionally, alarm new proposition patient is almost our to connectivity types. monthly personalization. We've updates value enhancing software with like across features GX software and improvements
As our one with new established lines customers. process example, of our have to of we the simplify in communication app engaging
experience, most engaging of to working on improve are behind focus the products this we operate market. type to We we the will constantly ensure the and with user-friendly scenes and the to continue that customer have
Our innovation. ecosystem, tomorrow leading associated you customers get and the know today the join DexCom when benefits that our with you all of
Our in also with with significant beyond of the people There intensive more covered are ever access reimbursement established now history, CGM coincided DexCom latest use. with cycle largest coverage expansion than to product before. has our company's insulin
million half As approximately non-insulin with U.S. insulin a represent the Medicare went age. that in live mid-April Medicare as basal as X certain individuals for type with people hypobychemia. using being well in X coverage reminder, people only Collectively, populations these diabetes nearly of X experience
commercial Encouragingly, continues for this to group. coverage build
We last live, since low early coverage of DexCom. now clear experienced continuation for a we by have outcomes the our market-leading patient With a new went customers. cohort. broad continue we our this immediate time. This out-of-pocket for to by and quarter levels cost established better this be that under potential in supports that of reimbursement seen further have transfer full recognize as an noted clearly we payers coverage driven very belt, quarter basal-only our prescribing uptick industry of once starts encouraged We trend
adjusted patterns fact, record new the landscape. have match prescribing QX we reimbursement in new another quarter delivered In patient Medicare to quickly start physicians as their
once trends coverage a come. adoption intensively as view things very type broad those available sign look for positive managed this experienced similar of diabetes. X to We previously we became very basal early, to While
segments trend quarter. our position. the have confident you patient incredibly this of market the and in all Importantly, sensor and our leading across reimbursed when channels with that gained this launch we GX, combine coverage technology, in broader Since U.S. feel we share continued
interest we channels, more are and in Even more CGM. DexCom among seeing non-reimbursed
dynamics seeing We also footprint. are our international similar across
have again result. this to took once compete globally perspective. We as share And a better been never we to a product international access capacity positioned from or quarter
product portfolio a we success. to people, past geographies was secured unique Senior continues to tailor offerings reimbursement our individual available, A where can meet reimbursement great having that this needs Dexcom Our France insulin intensive all we our of submitted structures. ONE contributor on this to around be quarter, therapy, the of the population. and key have X.X and products represents basal evidence multiple to people coverage which to this example extend for million By
scale working market each greater we've to commercial offerings, effectively. serve to In build and addition flexibility to advancing continuously our product more been
distributor facets As direct to been we key operations. have is and those levels through oversee recently to by these consents support drive Investor in to once Japan. go all strategic distribution. notable the performance as Along greater Historically, Day, markets discussed our we these at sales of lines, markets a we direct uptick focus provide one we from of conversion international and followed of way made in to scale the decision
last taking reimbursement became X to lives. anyone than As establish a broad for Japan one the first representing million year, more late of insulin countries reminder,
early quarter much of CGM very Despite stages, direct this, drive in over year. greater its adoption as to work the next market time remains initiate sales to will and second the continue we we in
to evidence new continue and range as of to DexCom's greater setting. added around real-time information CGM demonstrate DexCom the accountability type ASD after the month, our and Finally, study, diabetes our with we X position farm health distinctive this Dexcom a base decisions. product Study in substantial the evolving data of a we impact customers settings, behavior care within long-term patient ONE Warren adherence, diabetes metabolic care that pregnancy and at of performance therapy drive unique plays in a Across for cornerstone clinical outcomes and wide can role within landscape. change, providing the
to outcomes. interested better everyone and data to to else, that also been is care. and We appreciation believe drugs the to use to demonstrate an it encouraging the emerging play we latest solutions possible care drive these together important Like the in prefer drug therapies. for clinicians continuum, see these new CGM growing role best drugs see behind new need earlier Data with a have and the continues around
shared and ability features showed has for therapy, trends prescribing increase lifestyle GLP-X once fact, its CGM support for data we initiated someone that protective claims DexCom to this quarter as In management. clinicians favor
all we in data CGM clearly the at who these suggest As users generation therapy an would DexCom further those August dynamic faster update, in usage This therapy. pronounced looked of The newest among GLP-X trailing data that more CGM complementary not diabetes. XXXX XX-month of through are on demonstrates drugs. show regimes nature even than is across grows the this
mission we will launching control as that we ensure of we we to work role populations. empowering as of look the take non-insulin people our summer much across as next include products our forward, advancing broader to our our ecosystem This help. ongoing care well within continue as product As coming advance such unique clinical progress new of
story number touch. still can of potential the our early ultimately lives very We and in are of terms in we impact
Our future is incredibly bright.
third With that, Jereme? I will quarter for Jereme review to financials. of a over the turn it
